Research Progress on Integrated Traditional Chinese and Western Therapy for Parkinson’s Disease

doi:10.16153/j.1002-7777.2021.11.009

Chinese Pharmaceutical Affairs ›› 2021, Vol. 35 ›› Issue (11) : 1269-1275. DOI: 10.16153/j.1002-7777.2021.11.009

Research Progress

Shi Baoyan¹, Li Yan¹, Li Yue²

Author information +

History +

Abstract

Parkinson’s disease is a chronic, irreversible central nervous system degenerative disease with a slow degeneration of the substantia nigra striatum’s dopaminergic system. The main symptoms are loss or, degeneration or necrosis of dopaminergic neurons in substantia nigra, significant decrease of dopamine content in striatum, and formation of Lewy bodies by α-synuclein misfolding. Parkinson’s disease is a complex multifactorial and multigenetic disease that is influenced by both genetic and environmental factors, and a large proportion of Parkinson’s patients are caused by the combination of both. It is defined by clinical diagnosis as bradykinesia with tremor, rigor, or both. In addition to the above dynamic symptoms, it also acts as constipation, depression, dysosmia, sleep disorders and orthostatic hypotension symptoms. At present, no treatment can stop the progression of Parkinson’s disease. Dopaminergic drugs are the first choice for its treatment, but long-term use of dopaminergic drugs will lead to reduced efficacy and serious adverse reactions. The combination of Chinese medicine and Western medicine is more effective than a single medicine in reducing symptoms of Parkinson’sdisease and will achieve the effect of increasing efficacy and decreasing toxicity. Parkinson’s disease is incurable and has a certain degree of disability, which can affect the patients' abilities of learning and daily work, and it is a huge burden to patients and social economy. Therefore, exploring new treatments for Parkinson’s disease, improving patients' life quality, and delaying the development of symptoms of the disease are the focus of the current research.

Key words

Parkinson’s disease； treatment of Western medicines； TCM treatment； integrated traditional Chinese and Western therapy

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Shi Baoyan, Li Yan, Li Yue. Research Progress on Integrated Traditional Chinese and Western Therapy for Parkinson’s Disease[J]. Chinese Pharmaceutical Affairs, 2021, 35(11): 1269-1275 https://doi.org/10.16153/j.1002-7777.2021.11.009

References

[1] 于磊,李绍旦,刘毅,等.中药口服治疗帕金森病的疗效述评[J].中华中医药学刊,2016,34(3):563-565.
[2] 黄少东,梁健芬,陈月桥,等.中药治疗帕金森病的实验研究进展[J].中华中医药学刊,2020,38(10):47-51.
[3] Beitz JM.Parkinson's Disease:A Review[J].Front Biosci(Schol Ed),2014(6):65-74.
[4] Aubignat M,Tir M,Krystkowiak P.Non-motor Symptoms of Parkinson's Disease from Pathophysiology to Early Diagnosis[J].Rev Med Interne,2021,42(4):251-257.
[5] Véronneau-Veilleux F,Robaey P,Ursino M,et al.An Integrative Model of Parkinson's Disease Treatment Including Levodopa Pharmacokinetics,Dopamine Kinetics,Basal Ganglia Neurotransmission and Motor Action Throughout Disease Progression[J].Pharmacokinet Pharmacodyn,2021,48(1):133-148.
[6] 陈彪.左旋多巴在帕金森病治疗中的地位及进展[J].中国临床神经科学,2017,25(5):546-550.
[7] 周建丽,朱磊,杨凯,等.恩他卡朋双多巴治疗中晚期帕金森病疗效观察[J].老年医学研究,2021,2(2):6-8.
[8] 王海莲,金岩.中国七城市78家医院帕金森病患者处方用药现状研究[J].实用药物与临床,2017,20(11):1322-1326.
[9] Hametner EM,Seppi K,Poewe W.Pramipexole Extended Release in Parkinson's Disease[J].Expert Rev Neurother,2011,11(9):1229-1234.
[10] Xiang W,Sun YQ,Teoh HC.Comparison of Nocturnal Symptoms in Advanced Parkinson's Disease Patients with Sleep Disturbances:Pramipexole Sustained Release Versus Immediate Release Formulations[J].Drug Des Devel Ther,2018(12):2017-2024.
[11] 汪杰,李宏增,郭俊,等.盐酸普拉克索联合美多巴对老年帕金森病的临床疗效及对运动功能的影响[J].现代生物医学进展,2016,16(30):5879-5881.
[12] 申红菊.普拉克索片联合美多芭治疗帕金森病的临床价值分析[J].中国实用医药,2020,15(16):138-140.
[13] Zhang ZX,Liu CF,Tao EX,et al.Rotigotine Transdermal Patch in Chinese Patients with Advanced Parkinson's Disease:A Randomized,Double-blind,Placebo-controlled Pivotal Study[J].Parkinsonism Relat Disord,2017(44):6-12.
[14] Trenkwalder C,Kies B,Rudzinska M,et al.Recover Study Group.Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease:a Double-Blind,Randomized,Placebo-Controlled Study(RECOVER)[J].Mov Disord,2011,26(1):90-99.
[15] Rosa-Grilo M,Qamar MA,Taddei RN,et al.Rotigotine Transdermal Patch and Sleep in Parkinson's Disease:Where Are We Now[J].NPJ Parkinsons Dis,2017(3):28.
[16] Raeder V,Boura I,Leta V,et al.Rotigotine TransdermalPatch for Motor and Non-Motor Parkinson's Disease:AReview of 12 Years' Clinical Experience[J].CNS Drugs,2021,35(2):215-231.
[17] 梁金花.卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍患者的疗效观察[J].中国实用医药,2016,11(7):204-205.
[18] 高方.卡比多巴-左旋多巴控释片治疗帕金森病合并睡眠障碍的临床效果观察[J].首都食品与医药,2019,26(5):60.
[19] Müller T.Pharmacokinetic/Pharmacodynamic Evaluation of Rasagiline Mesylate for Parkinson's Disease[J].Expert Opin Drug Metab Toxicol,2014,10(10):1423-1432.
[20] Nagai M,Hattori N.Pharmacological Properties and Clinical Efficacy of Rasagiline Mesylate(Azilect?)[J].Nihon Yakurigaku Zasshi,2020,155(3):187-194.
[21] 陈霞,江骥.单胺氧化酶-B抑制药雷沙吉兰的临床药理学特征解析[J].武警医学,2016,27(3):309-312.
[22] Gallazzi M,Mauri M,Bianchi ML,et al.Selegiline Reduces Daytime Sleepiness in Patients with Parkinson's Disease[J].Brain Behav,2021,11(5):e01880.
[23] Henchcliffe C,Schumacher HC,Burgut FT.Recent Advances in Parkinson's Disease Therapy:Use of Monoamine Oxidase Inhibitors[J].Expert Rev Neurother,2005,5(6):811-821.
[24] 曲艳,李晓红.司来吉兰与雷沙吉兰治疗帕金森病的有效性和安全性对比[J].中国现代药物应用,2019,13(24):204-205.
[25] 苏红军.帕金森病药物治疗的研究进展[J].继续医学教育,2020,34(2):148-151.
[26] Kaakkola S.Clinical Pharmacology,Therapeutic Use and Potential of COMT Inhibitors in Parkinson's Disease[J].Drugs,2000,59(6):1233-1250.
[27] 孙斌.抗帕金森病新药——托卡朋与恩他卡朋[J].医药导报,2003(2):71-74.
[28] 赵银英,潘梦秋,卢健军,等.恩他卡朋添加治疗对帕金森病患者的疗效观察[J].中国现代药物应用,2017,11(7):19-21.
[29] 张雪,张雯,杜立达,等.抗帕金森病药物及其作用靶点研究进展[J].国际药学研究杂志,2016,43(1):87-96.
[30] Sahoo LK,Holla VV,Batra D,et al.Comparison of Effectiveness of Trihexyphenidyl and Levodopa on Motor Symptoms in Parkinson's Disease[J].J Neural Transm(Vienna),2020,127(12):1599-1606.
[31] 史君华,范惠先.盐酸苯海索治疗帕金森病及帕金森综合征的临床效果分析[J].河南医学研究,2018,27(5):900-901.
[32] 秦成玉.盐酸苯海索治疗帕金森病及帕金森综合征效果观察[J].临床合理用药杂志,2017,10(10):75-76.
[33] Elkurd MT,Bahroo LB,Pahwa R.The Role of ExtendedRelease Amantadine for the Treatment of Dyskinesia in Parkinson's Disease Patients[J].Neurodegener Dis Manag,2018,8(2):73-80.
[34] Dashtipour K,Tafreshi AR,Pahwa R,et al.ExtendedRelease Amantadine for Levodopa-Induced Dyskinesia[J].Expert Rev Neurother,2019,19(4):293-299.
[35] Li XZ,Zhang SN,Wang KX,et al.Neuroprotective Effects of Extract of Acanthopanax Senticosus Harms on SHSY5Y Cells Overexpressing Wild-type or A53T Mutant α-Synuclein[J].Phytomedicine,2014,21(5):704-711.
[36] 陈钧,韩明伟,付屺瞻,等.红景天苷对帕金森病轻度认知功能损害改善作用的研究[J].中华中医药杂志,2019,34(6):2455-2459.
[37] 张辉,马惠清,王晓娟.银杏叶提取物通过激活Nrf2-ARE信号通路对帕金森病大鼠发挥脑保护作用[J].沈阳:沈阳药科大学学报,2018,35(8):675-679,695.
[38] Han L,Xie YH,Wu R,et al.Traditional Chinese Medicine for Modern Treatment of Parkinson's Disease[J].Chin J Integr Med,2017,23(8):635-640.
[39] 赵长振.中药复方治疗帕金森病的用药规律研究[J].中国医药科学,2013,3(3):107-109,150.
[40] 蒋立华.止颤汤合柴胡加龙骨牡蛎汤治疗帕金森病合并抑郁症42例[J].中国中医药现代远程教育,2019,17(13):90-91.
[41] Zeng BY.Effect and Mechanism of Chinese Herbal Medicine on Parkinson's Disease[J].Int Rev Neurobiol,2017,(135):57-76.
[42] Sheng X,Yang S,Wen X,et al.Neuroprotective Effects of Shende'an Tablet in the Parkinson's Disease Model[J].Chin Med,2021,16(1):18.
[43] Jiang YN,Guo YZ,Lu DH,et al.Tianma Gouteng GranulesDecreases the Susceptibility of Parkinson's Disease by Inhibiting ALOX15-mediated Lipid Peroxidation[J].J Ethnopharmacol,2020,256:112824.
[44] Chen SY,Xiao SJ,Lin YN,et al.Clinical Efficacy and Transcriptomic Analysis of Congrong Shujing Granules in Patients with Parkinson's Disease and Syndrome of Shen(Kidney)Essence Deficiency[J].Chin J Integr Med,2020,26(6):412-419.
[45] Yeo S,Van Den Noort M,Bosch P,et al.A Study of the Effects of 8-week Acupuncture Treatment on Patients with Parkinson's Disease[J].Medicine(Baltimore),2018,97(50):e13434.
[46] Li Z,Chen J,Cheng J,et al.Acupuncture Modulates the Cerebello-Thalamo-Cortical Circuit and Cognitive Brain Regions in Patients of Parkinson's Disease with Tremor[J].Front Aging Neurosci,2018,(10):206.
[47] Cheng FK.The Use of Acupuncture in Patients with Parkinson's Disease[J].Geriatr Nurs,2017,38(4):302-314.
[48] 李云龙.针刺联合美多芭治疗帕金森病的120例临床研究[J].中外医疗,2015,34(22):120-121.
[49] Zhang ZJ,Ng R,Man SC,et al.Dense Cranial Electroacupuncture Stimulation for Major Depressive Disorder-a Single-blind,Randomized,Controlled Study[J].PLoS One,2012,7(1):e29651.
[50] Huang CH,Lin MC,Hsieh CL.Acupuncture Treatment Reduces Incidence of Parkinson's Disease in Patients with Depression:A Population-Based Retrospective Cohort Study in Taiwan[J].Front Aging Neurosci,2020,(12):591640.
[51] 葛玉杰,赵英霖.针药结合治疗帕金森病便秘39例临床观察[J].中国民族民间医药,2015,24(19):59-60.
[52] Yu SW,Lin SH,Tsai CC,et al.Acupuncture Effect and Mechanism for Treating Pain in Patients with Parkinson's Disease[J].Front Neurol,2019(10):1114.
[53] 刘焰刚,赵宇姝.推拿在帕金森氏病康复中的应用[J].中国中医药信息杂志,2002(12):56.
[54] 高志虹,顾沈红,马佩英,等.腹部穴位按摩对帕金森病患者功能性便秘的影响[J].解放军护理杂志,2013,30(5):72-73,76.
[55] McClurg D,Hagen S,Jamieson K,et al.Abdominal Massage for the Alleviation of Symptoms of Constipation in People with Parkinson's:A Randomised Controlled Pilot Study[J].Age Ageing,2016,45(2):299-303.
[56] Angelopoulou E,Anagnostouli M,Chrousos GP,et al.Massage Therapy as a Complementary Treatment for Parkinson's Disease:A Systematic Literature Review[J].Complement Ther Med,2020(49):102340.
[57] Casciaro Y.Massage Therapy Treatment and Outcomes for a Patient with Parkinson's Disease:a Case Report[J].Int J Ther Massage Bodywork,2016,9(1):11-18.
[58] Donoyama N,Ohkoshi N.Effects of Traditional Japanese Massage Therapy on Various Symptoms in Patients with Parkinson's Disease:A Case-series Study[J].J Altern Complement Med,2012,18(3):294-299.
[59] Miyahara Y,Jitkritsadakul O,Sringean J,et al.Can Therapeutic Thai Massage Improve Upper Limb Muscle Strength in Parkinson's Disease?An Objective Randomized-controlled Trial[J].J Tradit Complement Med,2018,8(2):261-266.
[60] 李炜大,汤占斌,韩有泽,等.帕金森病的临床治疗概况[J].现代生物医学进展,2019,19(10):1993-1996,1944.
[61] 杜广清,方伯言,刘爱贤,等.帕金森病患者康复治疗药物利用研究[J].中国医药,2020,15(11):1790-1794.